Related Experiment Videos

Coronary heart disease and polymorphisms in genes affecting lipid metabolism and inflammation

François Cambien1

  • 1INSERM U525, Chu Pitié-Salpétrière Université Pierre et Marie Curie, 91 Bd de l'Hôpital, 75013 Paris, France. cambien@chups.jussieu.fr

Current Atherosclerosis Reports
|April 7, 2005
PubMed

Insights

Genetic variations in lipid and inflammatory genes do not currently predict coronary heart disease (CHD) risk or guide treatment. A systems approach is needed to understand complex genetic interactions in CHD.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Atherosclerosis involves multiple biologic systems and genes.
  • Genetic variability is explored for its role in coronary heart disease (CHD) risk.
  • Focus on lipid and inflammatory genes' association with intermediate phenotypes and CHD.

Purpose of the Study:

  • To review recent findings on lipid and inflammatory genes in relation to CHD.
  • To assess the clinical utility of genetic polymorphism testing for CHD.
  • To explore the genetic basis of complex traits like CHD.

Main Methods:

  • Review of recent research on genetic polymorphisms in lipid and inflammatory pathways.
  • Analysis of the relationship between gene variability, intermediate phenotypes, and CHD.
  • Discussion of the need for a systems-based approach in genetic studies.

Main Results:

  • No current evidence supports the use of genetic polymorphism testing for CHD diagnosis or prognosis.
  • Genetic testing does not currently aid in tailoring drug prescriptions for CHD.
  • The relationship between specific gene variations and CHD risk remains complex and inconclusive.

Conclusions:

  • Genetic polymorphism testing for lipid and inflammatory genes offers no current clinical benefit for patients with CHD.
  • Understanding CHD genetics requires a systems approach, modeling gene-gene and gene-environment interactions.
  • Future research should focus on integrated models to unravel the complex genetic architecture of CHD.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...